Whole Exome Requisition Form

This requisition form, and consent forms in other languages, can be printed from **www.blueprintgenetics.com**, where test codes and detailed descriptions on tests are also available.

For support in North and South America: Phone: 1.833.697.4665 Fax: 1.650.446.7790



Keilaranta 16 A-B 02150 Espoo, Finland Phone: +358 40 2511 372 (Global) Fax: +358 9 8565 7177 (Global) support@blueprintgenetics.com

detailed descriptions on tests ar	e also availa	ble.		SU	upport@blueprintg	enetics.com	support@blueprintgenetics.com
			_				RE MARKED WITH AN ASTERISK (*)
TEST SELECTION*			Promo	otion	/Contract Cod	e:	
☐ Whole Exome	☐ Whole	Exome Family ⁱ⁾			ⁱ⁾ Sample ar included in	nd Informed Consent is the Family test.	needed from all family members
All tests include analysis of b	oth small ex	conic and splice site va	ariations, and la	arge o	deletions and inse	rtions.	
Sample type ⁱⁱ⁾ :	ood [Saliva DNA,	source:			Sample Co	llection Date:
ii) Please note that this information a	affects interp	retation for mitochondria	I DNA testing. M	lore in	formation about sar	nple requirements on blu	eprintgenetics.com/sample-requirement
ORDERING HEALTHCAR	E PROFE	SSIONAL INFORM	MATION				
*Name:			*In:	stitution:			
*Street address:				*Email:			
*City:	*Sta	*State:		Pho	one:		
*Zip/Post code:	*Country:			Fax:			
Delivery of results Mail	Fax	Nucleus Results v	will always be a	vailab	ole on our online re	eporting system at nuc	leus.blueprintgenetics.com.
Filtered variant results files and	raw data fi	les can be provided on	separate reque	st. Ple	ease contact suppo	ort@blueprintgenetics.c	om.
SHARE RESULTS WITH A	COLLEA	GUE					
Name:			Role/Title:				
Email:			Street addre	ess:			
City: State:			Zip/Post cod	Zip/Post code: Country:			
Phone:	Fax:		Mail Results Fax Results		Nucleus Results can be shared within the same hospital on our ordering portal, Nucleus.		
PATIENT INFORMATION	To enable (we recom	processing, provide at l mend using the patient	least two unique 's full name: firs	e pati st & la	ent identifiers that st name and date o	match those on the sai of birth).	nple label
* First name:				* Last name:			
* DOB: Year	/ Month / Day			Patient Identifier/MRN:			
FAMILY MEMBER 1 INFO	RMATIO	N (FILL ONLY IF WHO	LE EXOME FAN	MILY I	PRODUCT IS ORD	ERED)	
* First name:		* Last name:			* DOB: Identifier /MRN:		
* Relationship to patient:				Phenotype description:			
* Is family member 1 affected with the same phenotype as patient:							
Yes No P	artially	Uncertain					
FAMILY MEMBER 2 INFO	RMATIO	N (FILL ONLY IF WHO	LE EXOME FAI	MILY	PRODUCT IS ORD	ERED)	
* First name: * Last name:		* Last name:		* DOB:			Identifier /MRN:

If you wish to send more than two family members for Whole Exome Family test, please contact our support@blueprintgenetics.com.

Uncertain

WEU-2024.1-USLATAM Page 1/5

Phenotype description:

* Relationship to patient:

No

* Is family member 2 affected with the same phenotype as patient:

Partially

PATIENT HISTORY (DETAILED CLINICAL INFORMATION IS ESSENTIAL FOR ACCURATE INTERPRETATION OF RESULTS)

* Sex: Male Female	Female Unknown/uncertain		Ethnicity:			
* Has the patient or either of the family members received a hematopoietic stem cell transplantation? Yes No						
* Has the patient or either of the family members received granulocyte transfusions in the past two weeks? Yes No						
Age of primary diagnosis:						
Has the patient died? Yes No	When?					
* Describe all clinical findings (Attach possible supportive material.) Variants are reported based on the clinical information provided, therefore detailed phenotypic and clinical information increases the likelihood of a diagnosis.						
Affected family members: Yes No Who and what symptoms?						
Previous testing with normal results:		Previous testing with al	onormal results:			
Please specify genes of interest: Please specify suspected differential diagnosis (if applicable):						
CLINICAL FEATURES CHECKLIST						
Perinatal History	Endocrinological		Malformations – Brain			
☐ Cystic hygroma	□ Diabetes mellitus		☐ Abnormalities of basal ganglia			
☐ Increased nuchal translucency	☐ Hyperparathyroidis	m	☐ Agenesis of the corpus callosum			
☐ Intrauterine growth restriction	☐ Hypoparathyroidisr	n	☐ Brain atrophy			
□ Oligohydramnios	☐ Hyperthyroidism		☐ Cortical dysplasia			
□ Polyhydramnios	☐ Hypothyroidism		☐ Hemimegalencephaly			
☐ Prematurity	□ Paraganglioma		☐ Heterotropia			
☐ Other:	☐ Pheochromocytoma	а	☐ Holoprosencephaly			
	☐ Other:		☐ Hydrocephalus			
Cardiovascular			☐ Lissencephaly			
☐ Angioedema	Gastroenterological		☐ Macrocephaly			
☐ Aortic dilatation	☐ Constipation		☐ Microcephaly			
☐ Arrhythmia / conduction defect	☐ Chronic diarrhea		☐ Periventricular leukomalacia			
☐ Atrial septal defect			☐ Other:			
☐ Cardiomyopathy	☐ Elevated transaminases					
☐ Coarctation of aorta	☐ Gastroesophageal reflux		Malformations - Skeletal and Other			
☐ Hypoplastic left heart	☐ Gastroschisis		☐ Cleft lip / palate			
 Malformation of heart and/or great vessels 	☐ Hepatic failure ☐ Hirschsprung disease		☐ Club foot / feet☐ Contractures			
□ Stroke	☐ Pyloric stenosis		☐ Contractures ☐ Craniosynostosis			
☐ Tetralogy of Fallot	☐ Recurrent vomiting		☐ Dysmorphic features			
☐ Ventricular septal defect	☐ Tracheoesophageal	fistula	☐ Ear malformation			
□ Other:	□ Other:		☐ Fractures ☐ Limb anomaly			
Dermatological	Hematological and Imm	nunological	☐ Overgrowth			
☐ Blistering	☐ Anemia	-	☐ Polydactyly			
☐ Connective tissue abnormality	☐ Coagulation disorder		☐ Scoliosis			
☐ Hair abnormality	☐ Immunodeficiency		☐ Short stature			
☐ Pigmentation abnormality	☐ Myelofibrosis		☐ Syndactyly			
☐ Ichthyosis	☐ Neutropenia ☐ Vertebral anomaly		· · · · · · · · · · · · · · · · · · ·			
☐ Skin tumors	☐ Pancytopenia		☐ Other:			
☐ Nail abnormality ☐ Other:	☐ Thrombocytopenia☐ Other:					
□ Ottiet			1			

WEU-2024.1-USLATAM Page 2/5

CLINICAL FEATURES CHECKLIST Metabolic Neurodevelopmental (cont.) **Reproductive System Abnormalities** ☐ Abnormal creatine phosphokinase □ Psychiatric symptoms ☐ Ambiguous genitalia ☐ Elevated alanine ☐ Recurrent headache ☐ Cryptochidism ☐ Elevated puryvate □ Seizures ☐ Hypogonadism ☐ Failure to thrive □ Speech delay □ Hypospadias Ketosis Other:.... □ Infertility

☐ Lactic acidosis ☐ Undescended testis Neuromuscular ☐ Organic aciduria ☐ Other:..... ☐ Ataxia □ Other:..... ☐ Chorea **Tumors / Malignancies** Nephrological □ Dystonia ☐ Adenomatous polyposis Hypotonia ☐ Hydronephrosis □ Brain tumor Kidney malformation Hypertonia Breast cancer Muscle weakness ☐ Colorectal cancer Renal agenesis or dysgenesis Renal tubulopathy ☐ Muscular dystrophy □ Leukemia □ Other:..... Neuropathy ☐ Lung cancer □ Spasticity □ Melanoma Neurodevelopmental □ Other:..... □ Other:..... □ ADHD ☐ Autism spectrum disorder Ophthalmological ☐ Abnormal eye movement Developmental delay □ Developmental regression Abnormal vision Blindness □ Encephalopathy Fine motor delay П Cataracts ☐ Gross motor delay □ Coloboma ☐ CPEO ☐ Hearing loss Optic atrophy ☐ Intellectual disability □ Learning disability Ptosis

☐ Retinitis pigmentosa

□ Other:.....

* BILLING INFORMATION

☐ Obsessive-compulsive disorder

INSTITUTIONAL BILLING Please provide all details below if ordering for the first time or billing different than usual institution for this order.						
ICD-10 Codes:		Hospital status:				
			Inpatient O	utpatient	Non-hospital patient	
Facility name:		Street address:				
City:	State:	Zip/Post code:		Country:		
Contact person:		Phone:		Fax:		

ORDERING HEALTHCARE PROFESSIONAL SIGNATURE

I have discussed the Informed Consent for Whole Exome Sequencing with the patient or their legal guardian and possible family members included in the test (Whole Exome Family products). I have obtained any other consent from the patient and family members that is required under the laws of my country/state and/or federal laws. I certify that the test ordered is medically necessary for the diagnosis or detection of a disease, illness, impairment, symptom, syndrome or disorder. The results of this test will be used in the medical management of the patient and/or genetic counseling of the patient and family member(s). I have read and understood Blueprint Genetics' General Terms of Service, as currently posted at https://blueprintgenetics.com/general-terms/. Unless there is a written agreement between the Institution and Blueprint Genetics, accept, and have the authority to accept, these General Terms of Service on behalf of the Institution.			
* Signature:			
* Name:	* Date (YYYY-MM-DD):		

GENERAL TERMS

By placing the order the Customer accepts Blueprint Genetics' General Terms. Blueprint Genetics reserves the right to amend its General Terms, of which the latest version shall always be applied. The latest version can be found at https://blueprintgenetics.com/general-terms/

HEALTHCARE PROFESSIONAL SIGNATURE REQUIRED FOR PROCESSING

The Informed Consent for Whole Exome Sequencing is available in different languages at www.blueprintgenetics.com/how-to-order/. When ordering a Whole Exome Family product, please print out a separate Informed Consent for each family member.

INFORMED CONSENT

Whole Exome Sequencing

For more information on genetic testing for patients and family members, please visit: https://blueprintgenetics.com/resources/whole-exome-sequencing-guide-for-patients-and-families/

I confirm that the information below has been explained to me concerning the test:

- The results of this test may show that I and/or my family members have an inherited disease or are at an increased risk to be affected by a genetic disease. I understand that this test may detect previously unrecognized biological relationships, such as non-paternity.
- I am aware that the results of this test might be inconclusive about my genetic status. While some genetic variants are known to be disease causing and others are known to be benign, a portion of genetic variants found are of uncertain significance. Depending on the results of this test, my physician may recommend genetic counseling or further testing of myself and/or my family members.
- 3. I understand that an anonymized summary of results from this test may be presented for example at meetings, scientific publications, and/or DNA variant databases in order to improve the understanding, diagnostics, and treatment of similar clinical conditions. No identifying information will ever be presented.
- 4. If I have selected the patient insurance billing option, I authorize my health plan or insurance provider to pay my insurance benefits directly to Blueprint Genetics. I authorize Blueprint Genetics to release information concerning my testing to my insurer. I understand that I am legally responsible for sending Blueprint Genetics any money received from my insurance company for performance of this genetic test. If my insurance does not cover these services or only covers part of the amount, I am responsible for remaining costs of this test.
- 5. I am aware that not consenting to any of the sections to follow will not in any way affect my further treatment. If no box is checked in a section, it is assumed that no consent is given.
- 6. Separate consent for sample storage at Blueprint Genetics for 3 years for the purposes of family member testing. By checking the relevant box below I give my consent to the 3-year storage of the DNA sample in the diagnostic laboratory of Blueprint Genetics for the purposes of family member testing. Without this permission my sample will be stored approximately for 12 months and it is disposed of after that unless earlier disposal is required by applicable laws.

I give my consent to the 3-year storage of the sample for family member testing.

7. Separate consent for research use and long-term storage. By checking the relevant box below I give my consent to the long-term storage of the DNA sample in the diagnostic laboratory of Blueprint Genetics (without separate consent for long-term storage the DNA samples are typically stored for approximately 12 months) for use of the DNA sample in research into hereditary Mendelian diseases and the efforts to improve the diagnostics and treatment of said diseases. The research data concerning me will be treated as confidential information and coded in such a way that my identity cannot be discovered without the key code in the possession of the Blueprint Genetics research physician. Where necessary, such coded research data may also be processed within or outside the European Union and released for use by another research group or a company participating in the study. I hereby give my consent to the use of the aforementioned research data for the purposes set out in this consent. The data will be preserved for 50 years.

I understand that my consent to the research use of the sample taken for diagnostic purposes is voluntary and that I may cancel this consent and withdraw my participation at any time prior to the completion of the study. I am aware that the data collected up to the date of my withdrawal will be used as part of the research material.

I give my consent to the research use and long-term storage of the sample as set out in Section 7 above.

8. Separate consent for reporting of secondary findings. By checking the relevant box below I give Blueprint Genetics my consent to report to my ordering healthcare professional any possible secondary findings that are not directly related to the reason for ordering my test. Blueprint Genetics reports as secondary findings pathogenic and likely pathogenic variants in selected genes associated with various genetic disorders. The selected genes where secondary findings are reported represent those included in "ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing" published by the American College of Medical Genetics and Genomics.

I understand that secondary findings are of medical value and may have implications for my future health and for family planning purposes. I understand that the absence of secondary findings for any particular gene does not mean that there are no pathogenic variants in that gene.

Blueprint Genetics needs to receive this consent before sample is put into analysis in order to report any secondary findings. I understand that my family members can decide on their secondary findings independent of my decision.

I give my consent to the reporting of secondary findings.

More information about how we process personal data: https://blueprintgenetics.com/privacy/

☐ I give Blueprint Genetics permission to contact me regarding further genetic research and/or other genetic services relevant to me in the future. I may withdraw from such contact at any time.

PATIENT SIGNATURE

By signing this form, I acknowledge that I have read the Informed Consent for Whole Exome Sequencing and understand its content. I have had the opportunity to ask questions about this form and my questions have been answered.			
Patient name (please print):	Patient date of birth (YYYY-MM-DD):		
Patient signature:	Date (YYYY-MM-DD):		
Name and relationship of Legal Representative, if patient is a minor (please print):	Signature of Legal Representative, if patient is a minor:		

WEU-2024.1-USLATAM Page 5/5